Alverno Laboratories, a provider of high-quality diagnostic
testing services and one of the largest integrated laboratory
networks in the United States, and
Ibex Medical Analytics,
the leader in artificial intelligence (AI)-powered cancer
diagnostics, today announced the launch of the Ibex’s AI platform
in routine practice within Alverno’s laboratory network in Illinois
and Indiana. The phased launch encompasses AI-centric solutions for
cancer diagnosis across multiple tissue types, including prostate,
breast and gastric, that support pathologists and other physicians
in providing the utmost quality of care for their patients. The
laboratory system has recently completed phase 1 of its launch
plan, enabling AI-powered prostate cancer detection for prostate
biopsies, followed by breast and gastric.
Alverno serves over 30 hospital laboratories and
thousands of physician offices and other care facilities, touching
over 8 million patients’ lives per year across the Midwest. Alverno
was also among the first laboratories in the United States to
digitize its pathology services, harnessing the high-throughput
capabilities of the Philips IntelliSite Pathology Solution across
its system. The combined power of digital pathology and AI levels
up the services provided by Alverno to hospitals, physicians,
patients and caregivers by improving diagnostic accuracy and
turnaround time.
“When looking for an AI partner, we wanted a
shared vision for innovation yet a relentless drive for execution.
We chose Ibex because of its high-quality, innovative products and
customer service. Throughout our implementation and onboarding
process, the Ibex team was active and responsive, something not
always experienced when working on new projects,” said Sam Terese,
CEO and President of Alverno Laboratories. “For us, the notion of
going digital with AI is just something we would do, it's about who
we are. It's about delivering appropriate and great care to our
patients while speeding up time to results and ensuring the highest
possible quality result any lab can deliver, and we are really
thrilled to have a partnership with Ibex to help us along in that
journey.”
Ibex’s suite of solutions supports Alverno
pathologists in a variety of tasks during routine review of
prostate, breast and gastric biopsies. The solutions help with case
prioritization, AI-powered cancer detection and reporting and
optimization of immunohistochemistry workflows and other
productivity-enhancing tools. This implementation of AI on a large
scale across the entire laboratory network has the potential to
improve pathologists’ productivity and user experience, reduce
operational costs and improve overall service levels. Ibex is the
most widely deployed AI technology in pathology and is used as part
of everyday clinical practice at laboratories, hospitals and health
systems worldwide. Ibex demonstrated outstanding outcomes across
multiple clinical studies performed on various tissue types and
diagnostic workflows.1,2,3,4,5
“Alverno has a very clear commitment to
innovation and continually improving the delivery of care for its
community, and this commitment is demonstrated by the successful
implementation of the Ibex’s suite of solutions,” said Joseph
Mossel, CEO and Co-founder of Ibex Medical Analytics. “AI enables
Alverno pathologists to work more consistently, reproducibly and
efficiently to enable the highest level of diagnostic laboratory
services for the patients in the community for which they serve.
We're honored and excited to partner with their team and support
them in providing the highest quality of diagnostic services."
For additional information on Alverno
Laboratories, please visit alvernolabs.com and LinkedIn. For
additional information on Ibex Medical Analytics, please visit
ibex-ai.com, LinkedIn and X.
About Alverno Laboratories
Alverno Laboratories, located in Hammond, IN,
provides clinical and anatomic pathology services and testing to
communities throughout Illinois and Indiana. Alverno’s focus is
providing the best patient care utilizing advanced technologies
such as digital pathology, AI, Precision Medicine/Next-Gen
Sequencing and complex automation. As a joint venture between
Franciscan Alliance and Ascension Illinois, Alverno Laboratories
operates over 30 hospital laboratories and provides laboratory
testing to over 2,500 physician offices, freestanding urgent care
facilities, and research organizations. Innovation is at the center
of laboratory operations as demonstrated by the acquisition of one
of the largest digital pathology networks in the country. Digital
pathology, coupled with artificial intelligence technology, will
decrease turnaround times of oncology cases and enhance outcomes.
Advanced automation in microbiology rapidly increases the diagnosis
of bloodborne infections that can lead to sepsis.
About Ibex Medical
Analytics
Ibex Medical Analytics is transforming cancer
diagnostics with world-leading clinical grade AI-powered solutions
for pathology. Empowering physicians and supporting pathologists,
Ibex is on a mission to provide accurate, timely and personalized
cancer diagnosis for every patient. Ibex is the first and most
widely deployed AI-powered platform in pathology. Pathologists
worldwide use Ibex as part of their everyday routine to improve the
accuracy of cancer diagnosis, implement comprehensive quality
control measures, reduce turnaround times, and boost productivity
with more efficient workflows.
The Ibex suite includes solutions which are for
Research Use Only (RUO) in the United States and not cleared by the
FDA. Multiple solutions are CE marked (IVDD and IVDR) and
registered with the UK MHRA. For more information, including
indication for use and regulatory approval in other countries,
contact Ibex Medical Analytics.
[1] Pantanowitz et al., “An Artificial
Intelligence Algorithm for Prostate Cancer Diagnosis in Whole Slide
Images of Core Needle Biopsies: A Blinded Clinical Validation and
Deployment Study,” The Lancet Digital Health (Aug 2020)
[2] Sandbank et al., “Validation and Real-World
Clinical Application of an Artificial Intelligence Algorithm for
Breast Cancer Detection in Biopsies,” npj Breast Cancer 8, 129
(2022)
[3] Comperat et al., “Clinical Level AI-Based
Solution for Primary Diagnosis and Reporting of Prostate Biopsies
in Routine Use: A Prospective Reader Study, European Congress of
Pathology (2021)
[4] Raoux et al., “Novel AI-Based Solution for
Supporting Primary Diagnosis of Prostate Cancer Increases the
Accuracy and Efficiency of Reporting in Clinical Routine,” USCAP
(2021)
[5] Sandbank et al., “Validation and Clinical
Deployment of an AI-Based Solution for Detection of Gastric
Adenocarcinoma and Helicobacter pylori in Gastric Biopsies,” USCAP
(2022)
Paige Gonzalez, marketing manager
Alverno Laboratories
paige.gonzalez@alvernolabs.com